Cross-linking of IgGs bound on circulating neutrophils leads to an activation of endothelial cells: possible role of rheumatoid factors in rheumatoid arthritis-associated vascular dysfunction

Emmanuelle Rollet-Labelle1*, Myriam Vaillancourt1, Louis Marois1, Marianna M Newkirk3, Patrice E Poubelle2 and Paul H Naccache1

Abstract

Background: Rheumatoid arthritis is characterized by the presence of circulating auto-antibodies, including rheumatoid factors, which recognize the Fc portion of IgGs. The neutrophil is the most abundant circulating leukocyte and it expresses high levels of FcyRs on its surface. The aim of the present study was to examine the capacity of circulating human neutrophils to be activated by rheumatoid factors and the consequences of these events on endothelium.

Methods: Neutrophil-bound IgGs were cross-linked with anti-human IgGs to mimic the presence of circulating rheumatoid factors and FcyRs-dependent signalling events and functions were examined. The IgG and IgM composition of rheumatoid factors isolated from the serum of RA patients was characterized. Adhesion of neutrophils to endothelial cells was quantified in response to the addition of rheumatoid factors.

Results: Cross-linking of IgGs bound on neutrophils leads to FcyRs-dependent tyrosine phosphorylation, mobilisation of intracellular calcium and the extracellular release of superoxide anions and lysozyme. Incubation of endothelial cells with the supernatant of activated neutrophils increases ICAM-1 expression and IL-8 production by endothelial cells. Finally, rheumatoid factors enhance neutrophil adhesion to endothelial cells.

Conclusions: Our results show that activation of neutrophils' FcyRs by rheumatoid factors could participate in rheumatoid arthritis-associated vascular damage.

Keywords: Rheumatoid factors, Human neutrophils, FcyRs, Endothelial cells, Vascular damage
of IgGs. They are found in up to 80% of the sera of RA patients and represent a diagnostic and prognostic marker for RA even though they are detected in other autoimmune diseases and systemic infections [10]. RFs can enhance immune complex formation by interacting with circulating free IgGs, which are present at high concentrations (10 mg/ml) in human serum [11].

FcyRs specifically recognize the Fc portion of IgGs. Neutrophils, the most abundant circulating leukocytes, express at their surface high amounts of a specific and unique combination of FcyRs, namely FcγRIIa and FcγRIIib. These receptors play key roles in neutrophil phagocytosis as they participate in the recognition and phagocytosis of pathogens opsonized with IgGs. Neutrophils also possess a battery of cytotoxic enzymes that can be delivered within intracellular phagosomes to effect killing but may be inadvertently released extracellularly with deleterious consequences for the surrounding tissues [12]. FcyRs can also recognize naturally occurring immune complexes (ICs) and they play key roles in autoimmunity as they participate in the clearance of immune complexes which are abundant in the joint and circulation of RA patients [13,14]. Recently, an association of FcγRIIib copy number with the susceptibility to RF-positive RA was reported [15].

Since neutrophils are the major cells which infiltrate the synovial fluid and tissues [16] in RA, the activation of FcyRs on neutrophils is likely to play an important role in the chronic nature and the severity of the disease. Several murine models have been developed to test this hypothesis and to define the specific contribution of the different FcyRs [17,18]. Mice deficient in the common γ-signalling chain of FcyRs are not susceptible to arthritis induction; in contrast, the lack of the inhibitory receptor FcγRIIb exacerbates collagen-induced arthritis in susceptible mice [19]. However, as mouse and human FcyRs differ in their expression and cellular distribution, it is difficult to extrapolate results observed in mouse models to human diseases. Nevertheless, FcγRIIa has been implicated in RA as human FcγRIIa transgenic mice are susceptible to collagen-induced arthritis [19,20]. Neutrophil-selective transgenic expression of human FcγRIIa and FcγRIIib in this model indicates that these two receptors play non-redundant roles [13]. Belostocki et al. observed that FcγRIIa expression on circulating neutrophils was decreased during a longitudinal follow-up of RA patients receiving four infliximab infusions [21].

These data, together with the known role of neutrophils in tissue injury in IgG-mediated diseases and atherosclerosis, indicate that a detailed examination of the role of RFs on neutrophils and their potential implication in RA-associated vascular damage is warranted [22,23]. Whereas most of the neutrophil studies examine their roles outside the blood vessels, circulating neutrophils can have a pathological function in the systemic inflammatory condition that is characteristic of RA. In RA, circulating ICs first deposit in vasculature and FcγRIIib plays an important role in slowing down neutrophils leading to adhesion [24-26]. Neutrophils can then signal cytotoxic functions through, among others, FcyRs thus promoting tissue damage [27]. These data contributed to the elaboration of our hypothesis that IC and RF-containing IC can activate FcyRs on circulating neutrophils and participate in the development of RA-associated endothelium damage.

Methods

Antibodies and reagents

Antibodies

The anti-phosphotyrosine antibody (4G10, catalog no.05-321X) was purchased from Millipore (Billerica, MA). Horseradish peroxidase-labelled sheep anti-mouse IgGs (catalog no.NXA931) was obtained from GE Healthcare (Uppsala, Sweden). The anti-actin antibody (sc-1616) was obtained from Santa-cruz Biotechnology (Santa Cruz, CA). The anti-ICAM1 antibody (catalog no.BBA4) was obtained from R&D systems (Minneapolis, MN). Horseradish peroxidase-labelled anti-human IgGs, anti-human IgMs and anti-goat IgGs, FITC-labelled anti-human IgGs (catalog no.109-096-097) and anti-mouse IgGs (catalog no.115-096-071) and the rabbit anti-human IgGs (H + L) (catalog no.309-005-082) and rabbit anti-human IgGs, Fc fragment specific (catalog no.309-005-008) were obtained from Jackson ImmunoResearch (West Grove, PA). The anti-FcγRIIib Pelicluster (clone CLB-FcR-gran/1) (catalog no. M1389) was purchased from Sanquin (Amsterdam, The Netherlands). The anti-FcγRIIa antibody (clone IV.3) was purified from ascites of mice inoculated with hybridoma HB-217 obtained from the American Type Culture Collection (Manassas, VA).

Reagents

Calcein AM and Fura-2 AM were obtained from Invitrogen Life technologies (Burlington, ON). Cytochrome c was purchased from EMD chemicals (Mississauga, ON). Dextran T-500 and Micrococcus lysodeikticus were purchased from Sigma (Oakville, ON). Western lightning chemiluminescence plus was obtained from Perkin Elmer (Boston, MA). Ficoll-Paque and Heps were obtained from Wisent (St-Bruno, QC).

Isolation and stimulation of neutrophils

The collection of the blood was done with an appropriate consent form and approval of Laval University ethics committee. Neutrophils were aseptically isolated from healthy donors as previously described [28]. They were resuspended at 20x10⁶ cells/ml in Mg²⁺-free HBSS containing 1.6 mM of CaCl₂. Autologous platelet-poor
plasma (PPP) was prepared by centrifugation of whole plasma at 3000g for 10 minutes. To restore the physiologic amounts of bound IgGs on isolated cells, neutrophils were incubated for 20 minutes on ice with 10% autologous PPP followed by a 2 minutes centrifugation at 600xg. The neutrophils’ FcyRs were cross-linked by incubation with rabbit anti-human IgGs (20 μg/ml, final concentration) or with RFs (500 μg/ml) at 37°C for the times indicated in the legends of the figures. For FcyRs blocking experiments, antibodies IV.3 (2 μg/ml) (anti-FcyRIIa) and Pelicleuster (4 μg/ml) (anti-FcyRIIib) were added 10 minutes before incubation with autologous PPP. For the preparation of neutrophil supernatants, IgG were cross-linked with rabbit anti-human IgG antibody for 30 minutes at 37°C in the presence of 0.5% BSA. Neutrophils were then centrifuged (13000xg, 1 minute) and supernatants were collected and re-centrifuged before filtration on 0.22 μM membranes.

Electrophoresis and immunoblotting
Proteins were separated by SDS-PAGE on 7.5-15% or 10% acrylamide gels and transferred on PVDF membranes. They were then analyzed by immunoblotting as described in the legends of the figures.

Calcium mobilisation
Neutrophils were pre-incubated with 1 μM fura-2 AM for 30 minutes at 37°C in the presence of 0.5% BSA. The extracellular probe was removed by centrifugation and the cells were resuspended in HBSS at 5x10⁶ cells/ml and stimulated as described in the legend of the figures. Fluorescence was monitored in a fluorescence spectrophotometer (Fluorolog-SPEX from Jobin Yvon Inc., Edison, NJ) using two excitation wavelengths of 340 and 380 nm and an emission wavelength of 510 nm. The ratio of fluorescence values obtained at 340 and 380 nm was used as a measure of the intracellular levels of free cytoplasmic calcium.

Degranulation
The extent of lysozyme release was assessed by adding 100 μl of neutrophil supernatants to 900 μl of a 0.25 mg/ml Micrococcus lysodeikticus solution prepared in a 0.1M PO₄ buffer. The loss of absorbance was then monitored at 450 nm for 5 minutes and the rate of decrease of the absorbance provided a measure of the lysozyme activity present in the supernatants. The slopes were normalized to that of a cell lysate obtained by lysing the cells with 0.1% Triton X-100.

Superoxide production
Superoxide production was measured using the cytochrome c reduction assay. The absorption of cytochrome c was monitored at 550 nm and 540 nm and the amount of superoxide anions produced was calculated from the difference between the OD at the two wavelengths.

Culture and stimulation of HUVECs
Human umbilical vein endothelial cells (HUVECs) were obtained from Lonza (Basel, Switzerland). They were cultured in a humid atmosphere containing 5% CO₂ in EGM medium complemented with bovine brain extract as indicated by the company and used at passages 2–6. For the measurement of ICAM-1 expression and IL-8 production, HUVECs were seeded at 13x10⁴ cells/well in 6-well plates, grown for 24 hours and stimulated for 24 hours with the supernatants of control or IgGs-cross-linked human neutrophils diluted 1:1 in EGM complete medium. After stimulation, the supernatants of the HUVECs were collected and the cells were stimulated for another 24 hours with a new aliquot of the same supernatants of control or IgGs cross-linked human neutrophils diluted 1:1 in EGM complete medium following which the supernatants of the HUVECs were collected again.

Adhesion of neutrophils to endothelial cells
To obtain confluent monolayers, endothelial cells were seeded at 4–5 000 cells/well in 96-well plates and grown for 72–96 hours. Isolated neutrophils (20x10⁶/ml) were labeled in HBSS containing 5 μM calcein AM for 30 minutes at 37°C in the dark. PPP (10%, final concentration) was added to the neutrophil suspension for 20 minutes on ice following which the neutrophils were centrifuged and resuspended (5x10⁶/ml) in HBSS containing 0.8 mM MgCl₂. Neutrophils (25x10⁴ cells) were then added to the 96-well plates containing the confluent HUVEC monolayers and stimulated with anti-human IgGs antibody for 30 minutes or RFs for two hours at 37°C in a humid atmosphere containing 5% CO₂ in the dark. Non-adherent cells were washed away with cold PBS and the fluorescence of the plates resulting from the adhesion of calcein-labelled neutrophils to HUVECs was monitored at 485/530 nm (excitation/emission).

Preparation of rheumatoid factors
The collection of the blood was done with an appropriate consent form and approval of McGill University ethics committee. Selected sera from RF positive RA patients were pooled and centrifuged at 10,000 rpm for 15 minutes to remove any particulate matter. The supernatant was then made to a final concentration of 5% polyethylene glycol 6000 (by adding an equal volume of 10%) and mixed well. After 16 hrs at 4°C, the precipitates were collected by centrifugation for 15 minutes at 10,000 rpm. These precipitates were resuspended in PBS/azide to the original volume of the serum or plasma (and thus diluting out the PEG). The semi-purified RF-containing solutions were then stored at –20°C in a 50% glycerol solution to prevent damage from freeze thawing. Pentameric IgM precipitates at 5% PEG, whereas free IgG requires 10-12% PEG in order to precipitate from solution, thus the complexes collected using 5%
PEG are primarily those that result from the IgM RF recognition, although IgG RF complexes may also be present.

**Results**

As RFs recognize the Fc portion of IgG, they can form IC with circulating IgGs and deliver IgGs to neutrophils potentially leading to the activation of FcγR-dependent signalling pathways and functions. Alternatively, RFs may directly recognize surface-bound IgGs, cross-link them and, in so doing, activate neutrophils. Indeed, because of the high concentration of IgGs in plasma (10 mg/ml), neutrophils carry surface-bound IgGs in spite of the low affinity of FcγRs for monomeric IgGs. Although IgGs are dissociated from neutrophils after several washing steps [29], we postulated that incubation of isolated neutrophils with autologous plasma could restore the level of bound IgGs to that physiologically present on circulating neutrophils. We measured the amount of IgGs on freshly isolated neutrophils incubated with 10% of autologous PPP and compared it with the amount of IgGs measured on blood neutrophils (Figure 1A). The data confirm the loss of surface-bound IgGs on isolated neutrophils and indicate that incubation with 10% PPP leads to a recovery of an amount of bound IgGs similar to that present on circulating neutrophils. Furthermore, we also showed that plasma IgGs specifically bind to FcγRs as blocking these receptors with a combination of specific blocking antibodies to both anti-FcγRIIa and anti-FcγRIIib abrogated the binding of IgGs to isolated neutrophils (Figure 1B).

To test the hypothesis that the presence of RFs can lead to the activation of circulating neutrophils via their FcγRs, we used commercially available rabbit antibodies with the same antigenic characteristics as RFs, i.e. anti-human IgG antibodies. We first examined whether these antibodies could stimulate FcγR-dependent signalling pathways in human neutrophils. We previously showed that the specific engagement of FcγRIIa or FcγRIIib (cross-linking using monoclonal antibodies specific for FcγRIIa and FcγRIIib) leads to an increase of the tyrosine phosphorylation pattern of whole neutrophils lysates and to an intracellular mobilisation of calcium [31,32]. Figure 2 indicates that the addition of the anti-human IgG antibodies led to an enhancement of the FcγR-dependent tyrosine phosphorylation profile (see the proteins in the 60 to 120 kDa range) as well as to an increase in the level of free cytoplasmic calcium in isolated neutrophils pre-incubated with PPP. Both responses were decreased if the F(ab’)2 fragment of the anti-human IgG antibodies rather than the complete antibodies were used (Figure 2C and data not shown). This result indicates that these FcγR-dependent signalling pathways are in part activated by direct binding of anti-human IgG antibodies to free FcγRs. Furthermore, these responses were also decreased when neutrophils were not pre-incubated with PPP (Figure 2D and data not shown) confirming the capacity of anti-human antibodies to cross-link surface-bound IgGs.

The release of granule-contained proteolytic enzymes and the production of radical oxygen species are among the major means by which neutrophils destroy pathogens. However, these two functions will be deleterious for the cellular environment if misdirected (e.g., if these products are released into the extracellular milieu). As circulating neutrophils are continuously in contact with the vascular endothelium, we asked whether, in the context of RF-associated pathologies, cross-linking of surface-bound IgGs on neutrophils could trigger functions which impact on the integrity of the endothelium layer. It is relevant in this context to note that the extracellular release of lysozyme and superoxide anions has been described in response to the activation of neutrophils’ FcγRs [33-35]. We, therefore, examined these two functions in response to incubation with anti-human IgG antibodies. Cross-linking of surface-bound IgGs led to a 1.5 fold increase of the release of lysozyme and a 6 fold increase of

![Figure 1](link)
the production of superoxide anions by neutrophils in suspension over that of unstimulated cells (Figure 3). Both functions were inhibited in the presence of anti-FcγRs antibodies. These results illustrate the capacity of circulating neutrophils to release toxic compounds in the extracellular milieu when present in conditions resembling those present in RA.

Adhesion of neutrophils to endothelial cells is required in the context of innate immunity as neutrophils leave the vasculature to reach the inflammatory site. In the aseptic context of RA where blood-borne neutrophils encounter circulating ICs, we postulated that neutrophils will also be stimulated to adhere to the endothelium since activation of FcγRs leads to an increase of the expression and activation of adhesion molecules on neutrophils [36]. We tested this hypothesis by measuring the adherence of neutrophils to HUVECs. Calcein-labelled neutrophils were stimulated and incubated with endothelial cells for 30 minutes. We observed an increased capacity of stimulated neutrophils to adhere to endothelial cells (Figure 4). The adhesion is inhibited when neutrophils were pre-incubated with blocking anti-FcγR (Figure 4A) or anti-CD18 (Figure 4B) antibodies. Although the influence of blood flow is not considered in this static assay, this result indicates that cross-linking of IgGs bound on neutrophils leads to a β2-integrin-dependent adhesion of neutrophils to endothelial cells.

The results presented in Figure 3 show that neutrophils release superoxide anions and lysozyme into the extracellular medium subsequently to the cross-linking of surface-bound IgGs. Because of the capacity of stimulated neutrophils to adhere to endothelium (Figure 4), these mediators will be concentrated in the endothelial microenvironment. Accordingly, we next decided to examine the capacity of FcγRs-activated neutrophils to modulate the phenotype of endothelial cells. As we observed a β2-integrin-dependent increase in the adhesion of neutrophils subsequently to FcγR cross-linking, we examined the expression on the endothelial cells of the adhesion molecule ICAM-1, the counterpart of β2-integrins whose expression on endothelial cells is increased in response to inflammatory mediators [38]. We observed that ICAM-1 expression is increased when HUVECs were incubated for 48 hours with the supernatants of stimulated but not of control neutrophils (Figure 5A). We also measured the production of IL-8 by HUVECs as this chemokine plays a major role in

**Figure 2** Cross-linking of IgGs bound to human neutrophils leads to FcγR-dependent tyrosine phosphorylation and calcium mobilisation. A: Isolated neutrophils were incubated with 10% autologous PPP with or without FcγRs blocking monoclonal antibodies as described in Methods and Figure 1. Cross-linking of surface-bound IgGs was achieved by the addition of anti-human IgG antibodies. The reaction was stopped by transferring aliquots of the neutrophil suspensions directly in the same volume of boiling 2X concentrated modified Laemmli’s buffer [33]. Whole cell lysates (2.5x10⁵ cells in each lane) were analysed by SDS-PAGE and immunoblotted with anti-phosphotyrosine antibody 4G10 or anti-actin antibody (loading control). B: Isolated neutrophils were preincubated with Fura2-AM, followed by an incubation with or without FcγRs blocking antibodies and with 10% autologous PPP. Anti-human IgG antibodies were added and fluorescence was monitored as described in Methods. C: Cross-linking of surface-bound IgGs was achieved by the addition of either complete anti-human IgG antibodies or F(ab’) attendant human IgG antibodies. D: Neutrophils were incubated with or without PPP before cross-linking of surface bound IgGs. Results are representative of, at least, three independent experiments.
neutrophil adhesion and migration. HUVECs were incubated with neutrophil supernatants prepared as described above and IL-8 was measured by ELISA. We observed a slight but significant increase of soluble IL-8 production by HUVECs exposed to supernatants of stimulated neutrophils (Figure 5B). The amounts of IL-8 measured are likely to represent an underestimate of the actual amounts produced as secreted IL-8 by HUVECs will bind to extracellular aminoglycans residues of these cells and therefore will be undetectable by ELISA [38,39]. The release of IL-8 by stimulated and unstimulated neutrophils was also measured and the values were subtracted from the amounts measured in the supernatants of HUVECs.

Although the presence of RFs is associated with the severity of RA symptoms, very few studies have defined an abiological or pathologic function of these antibodies [40]. The results presented above suggest that RFs either as ligands of FcγRs or as antibodies recognizing membrane-bound IgGs might activate neutrophils. To verify this hypothesis, we decided to test the capacity of human RFs

Figure 3 Cross-linking of IgGs bound to human neutrophils leads to the secretion of superoxide anions and of lysozyme. Isolated neutrophils were incubated with 10% autologous PPP in the presence or absence of FcγRs blocking antibodies. A: Neutrophils were resuspended at 5x10^6 cells/ml in HBSS containing 125 μM of cytochrome c and anti-human IgG antibodies for 10 minutes at 37°C. The reaction was stopped by transfer on ice and the cells were removed by centrifugation. Results are expressed as mean +/- SEM of three independent experiments. * = P < 0.05 (Wilcoxon signed rank test). B: Anti-human IgG antibodies were added for 30 minutes and the neutrophil supernatants were prepared as described in Material and Methods. Lysozyme release and superoxide production were quantified as described in Methods. Results are expressed as mean +/- SEM of three independent experiments. * = P < 0.05 (Mann-Whitney test).

Figure 4 Cross-linking of surface-bound IgGs leads to the adhesion of neutrophils to endothelial cells. HUVECs were grown in 96 well plates until confluence. Neutrophils were incubated with calcein and with or without FcγRs blocking antibodies (A) or anti-CD18 antibody [37] (10 μg/ml) (B) before addition of PPP, as described in Methods. Neutrophils were then added to endothelial cells in the presence of anti-human IgG antibodies for 30 minutes. Non adherent neutrophils were discarded and the amount of adherent cells was quantified as the amount of fluorescence bound to endothelial cells. Results are expressed as mean +/- SEM of three independent experiments. * = P < 0.05, ** = P < 0.005, *** = P < 0.0005 (Mann-Whitney test).
to induce neutrophil adhesion to HUVECs as this experiment is performed in 96-well plates and consequently requires low amounts of RF. We first characterized the immunoglobulin composition of the RF preparation. An aliquot was submitted to SDS-PAGE followed by immunoblotting with anti-human IgG or anti-human IgM. We observed that this RF preparation is an IgM/IgG complex containing 5% IgM and 95% IgG, as estimated by densitometry (Figure 6A). Thus, the complexes collected using 5% PEG are the IgM-RFs bound to their cognate IgG antigen. Being a pentamer, IgM-RFs preferentially form immune complexes in the presence of IgGs. As the methods used to dissociate IgMs from IgGs (acid, high salt) can cause denaturation of the RF with resulting loss of binding activity, we used in the subsequent experiments the native RF preparation as such. We incubated neutrophils with the RF complexes and monitored their adhesion to HUVECs as in Figure 4. To assess that RF can bind membrane-bound IgGs, we performed these experiments without or with a pre-incubation of neutrophils with PPP on the adhesion capacity (see Figure 1). We observed an increase of adhesion to HUVECs when neutrophils were incubated with 500 μg/ml of purified RF and this adhesion was enhanced when neutrophils were pre-incubated with PPP (Figure 6B). This observation confirms the hypothesis that RFs can bind IgGs on neutrophils leading to cell activation. Adhesion was not modified in the presence of commercial non-specific IgM alone (data not shown). The relatively high concentration of RFs required for observing a functional effect when compared with the commercial anti-human cross-linking antibodies (20 μg/ml) is explained by the low concentration of IgM-RFs present in the preparation. Furthermore, as the affinity of most IgM-RFs for IgG is relatively low (of the order of 10^5 to 10^7) there is a constant on/off binding of the IgG-RF to IgGs or FcγR-bound IgGs. As we showed that the RF preparation was an IgG-containing complex, we tested the capacity of IgG complexes to enhance adhesion. Incubation of neutrophils with heat-aggregated IgGs (HA-IgGs, 100 μg/ml) enhances their adhesion to HUVECs in an FcγR-dependent manner (Figure 6C). Taken together, these results indicate that RFs from RA patients can activate neutrophils by recognizing either IgGs or FcγRs on neutrophils leading to an increased adhesion to endothelium.

**Discussion**

The mechanisms neutrophils use to kill microorganisms have the potential to alter or injure normal tissues [27]. Neutrophils’ Fc receptors illustrate this paradox. The best described role for neutrophils’ FcγRs is the optimization of the phagocytosis of IgG-opsonized pathogens [42-46]. However, these receptors are also involved in a variety of IgG-dependent processes including clearance of the naturally occurring immune complexes and the pathogenesis of auto-immune disorders such as RA [13]. Although RFs are present in the serum of the majority of RA patients and are a predictor of disease severity, their potential role in FcγRs activation and in RA pathogenesis is poorly characterized [47,48]. Yet, as IgG-IgM complexes (see Figure 6), RFs complexes represent potential ligands for FcγRs or for IgGs bound to FcγRs.

We observed that incubation of neutrophils with a preparation of RFs enhanced their ability to adhere to HUVECs. To our knowledge, this result represents the first observation of a biological effect of human RFs which could...
participate in the RA-associated vascular inflammation. In addition, we showed that activation of FcγRs of neutrophils with anti-human IgG antibodies which mimic the presence of RFs leads within 30 minutes to an extracellular release of lysozyme and superoxide anions concomitant with an enhancement of the adhesion of neutrophils to endothelial cells. These events may end up damaging the endothelium, a possibility supported by our observation that supernatants of neutrophils in which FcγRs have been cross-linked altered the phenotype of endothelial cells in an inflammatory direction (increased expression of ICAM-1 and production of IL-8). As IL-8 is a potent chemotactic mediator for neutrophils, the combined increase of IL-8 and ICAM-1 will lead to a positive activation loop of recruitment and adhesion of neutrophils with the potential to induce local vascular injury.

Few studies have characterized blood neutrophils of RA patients in spite of the demonstrated presence of circulating IC. Chronic peripheral activation of neutrophils in polyarticular juvenile RA has been reported and data suggest that blood neutrophils from RA patients have impaired FcγR-dependent bactericidal functions (superoxide production) [49,50]. On the other hand, generation of mice with neutrophil-selective expression of FcγRIIa and FcγRIIIb indicate that, in a model of soluble immune complexes deposited in the vasculature, FcγRIIIb is responsible for slowing down neutrophils thereby facilitating adhesion to endothelial cells [13,26]. Immobilized neutrophils may then activate FcγR-dependent cytotoxic functions and promote local endothelium damage. In innate immunity, by contrast, the vascular wall is rarely in contact with the toxic products of neutrophils as neutrophils leave the circulation by transendothelial migration. They arrive at the inflammation site where they release radical oxygen species and granular contents, most often in phagosome, thus preventing major damage to the cellular environment.

In humans, a similar mechanism of activation of FcγRs on circulating neutrophils has previously been described in anti-neutrophil cytoplasm autoantibody (ANCA)-associated diseases. These antibodies activate circulating neutrophils leading to vascular inflammation, a process in which FcγRs are directly involved. ANCAs are directed against enzymes stored in neutrophil granules but which have translocated to the plasma membrane in response to a minor inflammatory stimulus. The F(ab')2 portion of ANCAs engages the antigen and the Fc portion engages FcγRs. This FcγR-mediated interaction is required for neutrophil activation [51,52]. This mode of stimulation of neutrophils by ANCAs closely mimicks the mode of stimulation of RF proposed in the present study and argues for a role of RFs and RF-containing IC in RA-associated vascular inflammation. ANCAs-associated diseases, such as Wegener granulomatosis, clearly indicate...
that activation of circulated neutrophils can lead to vascular inflammation.

We showed that the circulating neutrophils possess membrane-bound IgGs which may be recognized by RFs leading to their activation. The mechanism of action of RF may require both the direct recognition of RF complexes by free FcγRs, such as HA-IgG and the binding of membrane-bound IgGs by RFs as pre-incubation of neutrophils with PPP enhances the RF-dependent activation of neutrophils.

Several data suggest that the affinity of FcγRIIa may be modulated by a priming signal such as fMLP, TNF or a mechanism including granular proteases [53,54]. This is of particular relevance in the inflammatory context of arthritis where elevated concentrations of various cytokines and mediators are present and may activate circulating neutrophils. A cytokine-dependent increase of FcγRs affinity would influence the amount of membrane-bound IgGs and consequently the RF-dependent activation of neutrophils of RA patients. Of direct relevance to the present study, the efficiency of anti-TNF therapy is related to a loss of function of FcγRIIa [21]. This effect may be mediated by the ability of TNF to modulate the functional responsiveness of FcγRIIa [55] and may, at least in part, explain the positive effects of anti-TNF therapy on endothelial dysfunction as previously proposed [56].

In the present study, we used a RF preparation purified from the sera of RA patients. This RF containing preparation is polyclonal, i.e., that it contained different populations of RFs (IgM and possibly IgG) with different specificities and affinities. The affinity of RFs for IgGs combined with the modulation of FcγR affinity for IgG by RA-associated cytokines will impact on the FcγR-dependent activation of neutrophils and consequently on the inflammation of the endothelium observed in RA patients. Further experiments using neutrophils from RA patients untreated or treated with anti-TNF therapy should help to understand not only the role of RA-associated cytokines on FcγR activity, but also the role of RF in the pathogenesis of RA.

In RA patients, high concentrations of RFs and the presence of extra-articular manifestations such as vasculitis are predictors of increased mortality, primarily from cardiovascular diseases [57]. Patients with ANCA-associated diseases (Wegener granulomatosis) also present higher risks to develop cardiovascular diseases [58]. On the other hand, FcγRs have been proposed to play a critical role in atherogenesis. Indeed, in apoE−/− mice (a model of human atherosclerosis), FcγRs appear to be important for the clearance of LDL-containing IC and apoE−/− mice deficient for the activating γ chain of FcγRs show less development and progression of atherosclerosis than apoE−/− mice which possess the γ chain of FcγRs [59]. These data support a role for leukocytes’ FcγRs in cardiovascular diseases associated with auto-immune diseases.

Systemic lupus erythematosus (SLE) is a chronic inflammatory disease also characterized by systemic inflammation and the presence of auto-antibodies and RF. Patients with SLE have an increased mean intima media thickness and SLE represents a risk factor for cardiovascular disease [60,61]. This indicates that the engagement of FcγRs of neutrophils and other immune cells may be involved in vascular dysfunction associated with various auto-immune inflammatory diseases.

Further examinations of neutrophil responses to RFs isolated from different patients are warranted. Indeed, the Ig composition, the affinity and the size of the RF complexes could influence neutrophil activation. Nevertheless, our results present a first report underlining the role of RFs in FcγR-dependent activation of circulating neutrophils and the potential consequences on systemic vascular inflammation. We previously characterized several of the pathways downstream of neutrophil’s FcγRs and we showed that both receptors cooperate for optimal FcγR-dependent responses [62,63]. In particular, FcγRIIb activation triggers a specific calcium signal [41]. As FcγRIIb is nearly exclusively expressed on human neutrophils, targeting this receptor or the FcγRIIb-dependent calcium signal, may represent an interesting clinical avenue which could help control RF-associated systemic inflammation in RA patients.

Conclusions

We show here that rheumatoid factors either by recognizing membrane-bound IgGs or by direct binding to FcγRs can activate circulating neutrophils. As this activation leads to adhesion to endothelial cells and may modify the phenotype of endothelial cells, we propose that it participates in the rheumatoid arthritis-associated vascular damages.

**Abbreviations**

ANCA: Anti-neutrophil cytoplasm autoantibody; FcγR: Fcgamma receptor; fMLP: N-formyl-methionyl-leucyl-phenylalanine; HUVECs: Human umbilical vein endothelial cells; IC: Immune complex; ICAM-1: Intercellular adhesion molecule-1; PPP: Platelet-poor plasma; RA: Rheumatoid arthritis; RF: Rheumatoid factors.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

ERL designed the study, performed the experiments, analysed the data and wrote the manuscript. MV performed several experiments and analysed data and statistics. LM participated in the design of the study and in the analysis of the data. MMN participated in the design of the study and provided material and expertise with RF. PEP revised the manuscript and provided clinical expertise and helpful discussions. PHN designed the study, critically analysed the data and supervised the preparation of the manuscript. All the experiments were performed in PHN’s laboratory. All authors read and approved the final manuscript.
References

1. Turesson C, Matteson EL: Vascularis in rheumatoid arthritis. Curr Opin Rheumatol 2009, 21:35–40.
2. Doyle MK: Vascularis associated with connective tissue disorders. Curr Rheumatol Rep 2006, 8:312–316.
3. Gabriel SE, Crowson CS, Kremers HM, Doran MF, Turesson C, O’Fallon WM, Matteson EL: Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 2003, 48:54–58.
4. Fietta P, Delante G: Atherosclerosis in rheumatoid arthritis: the 'rheumatoid vasculopathy'? Acta Biomed 2009, 80:177–186.
5. Moreland LW, Curtis JR: Systemic nonarticular manifestations of rheumatoid arthritis: focus on inflammatory mechanisms. Semin Arthritis Rheum 2009, 39:12–14.
6. Murdaca G, Colombo BM, Cagnati P, Gulli R, Spanò F, Puppo F: Endothelial dysfunction in rheumatic autoimmune diseases. Atherosclerosis 2012, 224:309–317.
7. Song YW, Kang HG: Autoantibodies in rheumatoid arthritis: rheumatoid factors and anticitrullinated protein antibodies. QJM 2010, 103:139–146.
8. Svensson I, Johansson J, Holmdahl R, Jonsson L: B cell-deficient mice do not develop type II collagen-induced arthritis (CA). Clin Exp Immunol 1998, 111:521–538.
9. Shatt J, Dixon FL: Serum transfer of collagen-induced arthritis in mice. J Exp Med 1983, 158:378–392.
10. Sutton B, Corper A, Bonagara V, Taussig M: The structure and origin of rheumatoid factors. Immunol Today 2000, 21:177–183.
11. Stoop JW, Zegers BJ, Sander PC, Baaleux RE: Serum immunoglobulin levels in healthy children and adults. Clin Exp Immunol 1969, 4:101–112.
12. Ali H, Hashiba B, Richardson RM, Snyderman R: Mechanisms of inflammation and leukocyte activation. Med Clin North Am 1997, 81:1–28.
13. Tsuji N, Asano K, Lauterbach M, Mayadas TN: Human neutrophil Fcγ receptors initiate and play specialized nonredundant roles in antibody-mediated inflammatory diseases. Immunity 2008, 28:833–846.
14. Nathan C: Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol 2006, 6:173–182.
15. Robinson JJ, Carr JM, Cooper DL, Rashid LH, Martin SG, Emery P, Isaacs JD, Barton A, Wilson AG, Barrett JH, Morgan AW: Confirmation of association of FCGR3B but not FCGR3A copy number with susceptibility to autoimmune positive rheumatoid arthritis. Hum Mutat 2012, 33:741–749.
16. Tak PP, Smeets TJ, Daha MR, Kluin PM, Meijers JA, Brand R, Meinders AE, Bredewold FC: Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum 1997, 40:217–225.
17. Boross P, Verbeek JS: The complex role of Fcγ receptors in the pathophysiology of arthritis. Springer Semin Immunopathol 2006, 28:339–350.
18. Tan Sardjono C, Mottram PL, van de Velde NC, Powell MS, Power D, Sibbire RC, Ricks JP, Campbell K, McKenzie SE, Brodo M, Stevenson AW, Hogarth PM: Development of spontaneous multisystem autoimmune disease and hypersensitivity to antibody-induced inflammation in Fcγ receptor-IIa-transgenic mice. Arthritis Rheum 2005, 52:3220–3229.
19. Kleinus S, Martinsson P, Heyman B: Induction and suppression of collagen-induced arthritis is dependent on distinct Fcγ receptors. J Exp Med 2000, 191:1611–1616.
20. van de Velde NC, Mottram PL, Powell MS, Lim B, Holmdahl R, Hogarth PM: Transgenic mice expressing human FcγRIIIa have enhanced sensitivity to induced autoimmune arthritis as well as elevated Th17 cells. Immunol Lett 2010, 130:82–88.
21. Belostocki K, Park MS, Redecha FB, Masuda E, Salmon JE, Picrop L: FcγRIIIa is a target for modulation by TNFalpha in human neutrophils. Clin Immunol 2005, 117:76–86.
22. Mayadas TN, Tsokos GC, Tsudo N: Mechanisms of immune complex-mediated neutrophil recruitment and tissue injury. Circulation 2009, 120:2012–2024.
23. Baeta R, Corini A: Role of polymorphonuclear neutrophils in atherosclerosis: current state and future perspectives. Atherosclerosis 2010, 210:1–13.
24. Normen MJ, Van de Velde NC, Timoshanko JR, Isselbe K, Hickey MJ: Overlapping roles of endothelial selectins and vascular cell adhesion molecule-1 in immune complex-induced leukocyte recruitment in the cremasteric microvasculature. Am J Pathol 2003, 163:1491–1503.
25. Stokol T, O’Dornell P, Xiao L, Knight S, Stavrakis G, Botton M, von Andrian UH, Mayadas TN: C1q governs deposition of circulating immune complexes and leukocyte Fcγ receptor interactions in human neutrophils. J Exp Med 2004, 200:843–846.
26. Skillbeck CA, Lu X, Sheikh S, Savage CG, Nash GB: Capture of flowing human neutrophils by immobilised immunoglobulin: roles of Fc-receptors CD16 and CD32. Cell Immunol 2006, 241:26–31.
27. Segel GB, Halterman MW, Lichtman MA: The paradox of the neutrophil’s role in tissue injury. J Leukoc Biol 2011, 89:359–372.
28. Rollet E, Caon AC, Noberge CJ, Liao NW, Malawista SE, McColl SR, Naccache PH: Tyrosine phosphorylation in activated human neutrophils—comparison of the effects of different classes of agonists and identification of the signaling pathways involved. J Immunol 1994, 153:353–363.
29. van Mier E, Teeling JL, van der Meer JW, Beeker WK, Hack CE: Monomeric IgG in intravenous Ig preparations is a functional antagonist of FcγRIIIa and FcγRIIB. J Immunol 2004, 173:353–339.
30. Desmeules P, Dufoix M, Fernandez MJ: A rapid flow cytometry assay for the assessment of calcium mobilization in human neutrophils in a small volume of lysed whole-blood. J Immunol Methods 2009, 340:154–157.
31. Rollet-Labelle E, Marois S, Barbeau K, Malawista SE, Naccache PH: Recruitment of the cross-linked opsonic receptor CD32A (FcγRIIA) to high-density detergent-resistant membrane domains in human neutrophils. Biochem J 2004, 381:919–928.
32. Fernandes MJ, Rollet-Labelle E, Pare G, Marois S, Tremblay ML, Teilraud JL, Naccache PH: CD16b associates with high-density, detergent-resistant membranes in human neutrophils. Biochem J 2006, 393:351–359.
33. Fernandes MJ, Lachance G, Pare G, Rollet-Labelle E, Naccache PH: Signaling through CD16b in human neutrophils involves the Tεc family of tyrosine kinases. J Leukoc Biol 2005, 78:524–532.
34. Fossati G, Bucknall RC, Edwards SW: Insoluble and soluble immune complexes activate neutrophils by distinct activation mechanisms: changes in functional responses induced by priming with cytokines. Ann Rheum Dis 2002, 61:3–19.
35. Rollet-Labelle E, Gilbert C, Naccache PH: Modulation of human neutrophil responses to CD32 cross-linking by serine/threonine phosphatase inhibitors: Cross-talk between serine/threonine and tyrosine phosphorylation. J Immunol 2000, 164:1020–1028.
36. Ortiz-Stern A, Rosales C: Fc(γ)RIIA/RBB2 stimulation promotes beta(1) integrin activation in human neutrophils. J Leukoc Biol 2005, 77:787–799.
37. Naccache PH, Jean N, Liao NW, Bator JM, McColl SR, Kubes P: Regulation of stimulated integrin surface expression in human neutrophils by tyrosine phosphorylation. Blood 1994, 84:616–624.
38. Kukulski F, Ben Yebdri F, Bahrami F, Fausther M, Tremblay A, Sevigny J: Endothelial P2Y2 receptor regulates LPS-induced neutrophil transendothelial migration in vitro. Mol Immunol 2010, 47:9901–999.
39. Middleton J, Patterson AM, Gardner L, Schmutz C, Ashton BA: Leukocyte extravasation: chemokine transport and presentation by the endothelium. Blood 2002, 100:3853–3860.
40. Alessandri C, Bombardieri M, Papa N, Cinquini M, Magrini L, Tincani A, Valesini G: Decrease of intracellular citrullinated peptide antibodies and rheumatoid factor following anti-TNF alpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 2004, 63:1218–1221.
41. Marois L, Pare G, Vaillancourt M, Rollet-Labelle E, Naccache PH: Fc(γ)RIIb Triggers Raft-dependent Calcium Influx in IgG-mediated Responses in Human Neutrophils. J Biol Chem 2011, 286:3509–3519.
42. Lowry MB, Duchemin AM, Robinson JM, Anderson CL: Functional separation of pseudopod extension and particle internalization during Fc gamma receptor-mediated phagocytosis. J Exp Med 1998, 187:161–176.

43. Indik ZK, Park JG, Hunter S, Schreiber AD: The molecular dissection of Fc gamma receptor-mediated phagocytosis. Blood 1995, 86:4389–4399.

44. Hunter S, Ramouni M, Schreiber AD: Transfection of an Fc gamma receptor cDNA induces T cells to become phagocytic. Proc Nat Acad Sci USA 1994, 91:10232–10236.

45. Edberg JC, Salmon JE, Kimberly RP: Functional capacity of Fcgamma receptor-III (CD16) on human neutrophils. Immunol Res 1992, 11:239–251.

46. Edberg JC, Kimberly RP: Modulation of Fcgamma and complement receptor function by the glycosyl-phosphatidylinositol-anchored form of FcgammaRIII. J Immunol 1994, 152:5826–5835.

47. Newkirk MM: Rheumatoid factors: what do they tell us? J Rheumatol 2002, 29:2034–2040.

48. Nowak UM, Newkirk MM: Rheumatoid factors: good or bad for you? Int Arch Allergy Immunol 2005, 138:180–188.

49. Jarvis JN, Petty HR, Tang Y, Frank B, Tessler PA, Dozmorov I, Jiang K, Kindzelski A, Chen Y, Cadwell C, Turner M, McGhee JI, Centola M: Evidence for chronic, peripheral activation of neutrophils in polyarticular juvenile rheumatoid arthritis. Arthritis Res Ther 2006, 8.R154.

50. Fairhurst AM, Wallace PK, Jawad AS, Goulding NJ: Rheumatoid peripheral blood phagocytes are primed for activation but have impaired Fc-mediated generation of reactive oxygen species. Arthritis Res Ther 2007, 9:R29.

51. Hewins P, Williams JM, Wakelam MJ, Savage CO: Activation of Syk in neutrophils by antineutrophil cytoplasm antibodies occurs via Fcgamma receptors and CD18. J Am Soc Nephrol 2004, 15:796–808.

52. Williams JM, Ben-Smith A, Hewins P, Dove SK, Hughes P, McEwan R, Wakelam MJ, Savage CO: Activation of the G(i) heterotrimeric G protein by ANCA IgG F(ab')2 fragments is necessary but not sufficient to stimulate the recruitment of those downstream mediators used by intact ANCA IgG. J Am Soc Nephrol 2003, 14:661–669.

53. van de Winkel JG, van Ommen R, Huizinga TW, de Raad MA, Tuinman WB, Groenen PJ, Capel PJ, Koene RA, Tax WJ: Proteolysis induces increased binding affinity of the monococyte type II FcR for human IgG. J Immunol 1989, 143:571–578.

54. Nagasnjaj S, Venketesan K, Anderson M, Sayed U, Zhu C, Selvaraj P: Cell-specific, activation-dependent regulation of neutrophil CD32A ligand-binding function. Blood 2000, 95:1069–1077.

55. Belostocki K, Priscop L, Redecha PB, Aydin A, Leff L, Harrison MJ, Salmon JE: Infliximab treatment shifts the balance between stimulatory and inhibitory Fcgamma receptor type II isoforms on neutrophils in patients with rheumatoid arthritis. Arthritis Rheum 2008, 59:384–388.

56. Murdaca G, Spanò F, Cagnati P, Puppo F: Free radicals and endothelial dysfunction: Potential positive effects of TNF-a inhibitors. Redox Rep 2013, 18:95–99.

57. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE: Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005, 52:722–732.

58. Suppiah J, Judge A, Batra R, Flosmann O, Harper L, Hoglund P, Javaid MK, Jayne D, Mulhysen C, Westman K, Davis JC, Hoffman GS, McCune WJ, Merkel PA, St Clair EW, Seo P, Spiera R, Stone JH, Luzzani R: A model to predict cardiovascular events in patients with newly diagnosed Wegener’s granulomatosis and microscopic polyangiitis. Arthritis Care Res (Hoboken) 2011, 63:588–596.

59. Hernandez-Vargas P, Ortiz-Munoz G, Lopez-Franco O, Suzuki Y, Gallego-Delgado J, Sanjuan G, Lazaro A, Lopez-Parra V, Ortega L, Egido J, Gomez-Guerrero C: Fcgamma receptor deficiency confers protection against atherosclerosis in apolipoprotein E knockout mice. Circ Res 2006, 99:1188–1196.

60. Colombo BM, Cacciapaglia F, Puntoni M, Murdaca G, Rossi E, Rodriguez G, Nobili F, Pisciotta L, Bertolini S, Moccetti T, Dentali F, Steidl L, Ciprandi G, Afeltra A, Indiveri F, Puppo F: Traditional and non traditional risk factors in accelerated atherosclerosis in systemic lupus erythematosus: role of vascular endothelial growth factor (VEGATS Study). Autoimmun Rev 2009, 8:309–315.

61. Colombo BM, Murdaca G, Calti M, Rodriguez G, Grassia L, Rossi E, Indiveri F, Puppo F: Intima-media thickness: a marker of accelerated atherosclerosis in women with systemic lupus erythematosus. Ann N Y Acad Sci 2007, 1108:121–126.